AirSculpt Technologies (NASDAQ:AIRS) Posts Earnings Results, Misses Estimates By $0.04 EPS

AirSculpt Technologies (NASDAQ:AIRS) released its quarterly earnings results on Monday. The company reported ($0.02) earnings per share for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.04), Zacks reports. The company had revenue of $42.90 million during the quarter, compared to analyst estimates of $44.14 million. AirSculpt Technologies had a negative return on equity of 4.98% and a negative net margin of 7.39%.

Here are the key takeaways from AirSculpt Technologies’ conference call:

• Business stabilization continued: Q2 revenue was $42.9 million, down 2.5% year over year, but same-center case volume rose 1%, marking a second consecutive quarter of case growth. Same-center sales improved 21 percentage points year over year and were roughly flat for the first half.
• AirSculpt is expanding its procedure portfolio to address GLP-1-related body-contouring needs. Skin excisions reached more than 200 procedures in Q2, while the new AlloClae partnership is expected to begin rolling out later this quarter and is not yet included in guidance.
• Management said consumer trends softened in June and continued into July, prompting expectations for comparable Q3 revenue to decline by a single-digit percentage. Full-year revenue guidance was reaffirmed at the lower end of the prior range, while adjusted EBITDA guidance was reduced to $12 million–$14 million due partly to an additional $5 million marketing investment.
• Higher marketing investment has yet to fully translate into efficiency, with customer acquisition cost increasing to approximately $3,500 per case from roughly $2,900 a year ago. Adjusted EBITDA declined to $4.9 million, or 11.5% of revenue, from $5.8 million in the prior-year quarter.
• Liquidity and debt metrics improved, with approximately $24 million of available liquidity at quarter-end, $44 million of gross debt, and a term-loan maturity extension to November 2027. Management also reported roughly $20 million raised through its ATM program year to date and $13 million of debt repayment.

AirSculpt Technologies Trading Down 45.1%

Shares of AIRS opened at $2.75 on Tuesday. AirSculpt Technologies has a twelve month low of $1.51 and a twelve month high of $12.00. The firm has a market capitalization of $194.01 million, a P/E ratio of -16.18 and a beta of 2.33. The company has a current ratio of 0.75, a quick ratio of 0.75 and a debt-to-equity ratio of 0.39. The stock’s fifty day simple moving average is $4.69 and its 200 day simple moving average is $3.56.

AirSculpt Technologies News Roundup

Here are the key news stories impacting AirSculpt Technologies this week:

• Positive Sentiment: Strategic expansion: AirSculpt entered an exclusive partnership with AlloClae to offer an injectable adipose matrix, broadening its body-contouring services and potential patient base. AirSculpt anticipates $12M-$14M adjusted EBITDA while rolling out AlloClae partnership
• Positive Sentiment: Improved balance-sheet flexibility: The company reported approximately $18.8 million in cash, reduced gross debt by about $30 million to $44.2 million, and extended its term-loan maturity to November 2027. AirSculpt Technologies Reports Second Quarter Fiscal 2026 Results
• Neutral Sentiment: Underlying demand was relatively stable: Same-center case volume increased 1.0% year over year in the quarter, while full-year revenue guidance was reaffirmed at approximately $151 million to $157 million, albeit at the lower end of the range.
• Negative Sentiment: Quarterly performance missed expectations: Revenue fell 3% year over year to $42.9 million, below the $44.14 million consensus estimate, while adjusted EBITDA declined 16.2% to $4.9 million. The company posted a $0.02-per-share loss versus analyst expectations for $0.02 of earnings. AirSculpt Technologies Shares Sink on Wider 2Q Loss, Outlook Cut
• Negative Sentiment: Profitability outlook was cut: AirSculpt reduced 2026 adjusted EBITDA guidance to approximately $12 million-$14 million, reflecting pressure from higher marketing investment, lower revenue per case, and operating costs. Net loss widened to $1.1 million from $0.6 million a year earlier.
• Negative Sentiment: Potential dilution remains a concern: The company raised $5 million through its at-the-market offering, and its amended loan agreement requires 50% of net proceeds from future equity issuances to repay term loans.

Analysts Set New Price Targets

Several research analysts recently weighed in on the stock. Wall Street Zen raised shares of AirSculpt Technologies from a “hold” rating to a “buy” rating in a research note on Saturday, June 27th. Weiss Ratings upgraded shares of AirSculpt Technologies from a “sell (e+)” rating to a “sell (d-)” rating in a report on Wednesday, July 1st. Finally, Leerink Partners set a $4.50 price objective on shares of AirSculpt Technologies in a research report on Thursday, May 14th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Reduce” and an average price target of $4.50.

Institutional Investors Weigh In On AirSculpt Technologies

Several institutional investors and hedge funds have recently added to or reduced their stakes in AIRS. Balyasny Asset Management L.P. lifted its stake in shares of AirSculpt Technologies by 128.5% in the 2nd quarter. Balyasny Asset Management L.P. now owns 1,113,843 shares of the company’s stock valued at $5,380,000 after purchasing an additional 626,309 shares in the last quarter. Renaissance Technologies LLC purchased a new position in AirSculpt Technologies in the fourth quarter valued at approximately $1,991,000. Vanguard Group Inc. raised its holdings in AirSculpt Technologies by 10.8% in the third quarter. Vanguard Group Inc. now owns 782,543 shares of the company’s stock valued at $6,276,000 after buying an additional 76,291 shares during the period. Geode Capital Management LLC lifted its position in AirSculpt Technologies by 4.6% during the fourth quarter. Geode Capital Management LLC now owns 403,163 shares of the company’s stock valued at $798,000 after buying an additional 17,889 shares in the last quarter. Finally, Saba Capital Management L.P. purchased a new stake in AirSculpt Technologies during the fourth quarter worth approximately $620,000. 91.54% of the stock is currently owned by institutional investors and hedge funds.

AirSculpt Technologies Company Profile

AirSculpt Technologies, Inc (NASDAQ: AIRS) is a medical technology company specializing in minimally invasive body contouring. The company’s flagship AirSculpt® platform combines pneumatic power with precision microcannulas to deliver fat removal, transfer and sculpting procedures. AirSculpt Technologies partners with both company-owned and franchised cosmetic surgery practices to offer a streamlined, office-based alternative to traditional liposuction.

Through its proprietary system, AirSculpt Technologies provides both consumers and medical professionals with an integrated solution that emphasizes reduced downtime, smaller incision sites, and more predictable outcomes.